TG Therapeutics (NASDAQ:TGTX) has signed a multi-year manufacturing provide settlement with FUJIFILM Diosynth Biotechnologies (OTCPK:FUJIY) for its a number of sclerosis drug.
Beneath the deal, FUJIFILM Diosynth will present secondary US-based manufacturing provide for Briumvi, TG Therapeutics’ FDA-approved drug for relapsing type of a number of sclerosis, on the firm’s new biopharmaceutical manufacturing facility in North Carolina. The ability will probably be totally operational in 2025.
Shares of FUJIFILM Diosynth have been up roughly 4%, whereas TG Therapeutics (NASDAQ:TGTX) misplaced 10% on Monday following quarterly outcomes.
Supply: Press Launch
Beneath the deal, FUJIFILM Diosynth will present secondary US-based manufacturing provide for Briumvi, TG Therapeutics’ FDA-approved drug for relapsing type of a number of sclerosis, on the firm’s new biopharmaceutical manufacturing facility in North Carolina. The ability will probably be totally operational in 2025.
Shares of FUJIFILM Diosynth have been up roughly 4%, whereas TG Therapeutics (NASDAQ:TGTX) misplaced 10% on Monday following quarterly outcomes.
Supply: Press Launch
